4359 |
TAVR is Better |
Eberhard Grube |
Apr. 20. 23 |
4358 |
PROTECTED-TAVR: Statistical or Clinical Interpretation and My Take-Home Messages |
Samir R. Kapadia |
Apr. 20. 23 |
4357 |
Next Innovation in Transcatheter Valve Intervention: New Techniques and New Valves |
Tullio Palmerini |
Apr. 20. 23 |
4356 |
How Recent Guidelines will Change the Practical Indication of TAVR in the Coming Years? |
Alan C. Yeung |
Apr. 20. 23 |
4355 |
The 20th Anniversary of TAVR Ceremony - From Concept to Human Application |
Alain G. Cribier |
Apr. 20. 23 |
4354 |
BRIGHT-4 Trial; Bivalirudin with a Post-PCI High-Dose Infusion vs. Heparin Monotherapy During Primary PCI in STEMI |
Gregg W. Stone |
Apr. 20. 23 |
4353 |
Updated Evidence and Recommendation of Antithrombotic Therapy after TAVR |
George D. Dangas |
Apr. 20. 23 |
4352 |
Edoxaban vs. DAPT for Valve Thrombosis and Cerebral Thromboembolism After TAVR: Deep-Dive into ADAPT-TAVR Trial |
Duk-Woo Park |
Apr. 20. 23 |
4351 |
Recommendation, Guided vs. Potent P2Y12 Inhibitor Therapy: Updated Evidence |
Pieter Smits |
Apr. 20. 23 |
4350 |
P2Y12 Inhibitor or Asprin for Long-term Antiplatelet Management |
Kyung Woo Park |
Apr. 20. 23 |